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We present a rare case of microgranular variant acute promyelocytic leukemia (APL) associated with ider(17)(q10)t(15;17)(q22;q12) 
of an old-age patient. The initial chromosome study showed a 46,XX,del(6)(?q21q25),der(15)t(15;17)(q22;q12),ider(17)(q10)t(15;17) 
[10]/47,sl,+ider(17)(q10)t(15;17)[3]/46,XX[16]. FISH signals from a dual color dual fusion translocation PML-RARA probe were con-
sistent with the results of conventional cytogenetics. Because of the rarity of ider(17)(q10)t(15;17) in microgranular APL, further 
studies on both gene dosage effect of this chromosomal abnormality and the influence of ider(17)(q10)t(15;17) on clinical features 
such as prognosis, survival, and treatment response of APL cases are recommended.
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INTRODUCTION
Acute promyelocytic leukemia (APL) is one of the most 
characteristic subtypes of AML in which abnormal promy-
elocytes predominate within peripheral blood or bone mar-
row [1]. Also, t(15;17)(q22;q21) shows a characteristic 
chromosomal translocation in APL, observable in 70-90% 
of APL patients. Owing to all trans-retinoic acid (ATRA) 
combined with chemotherapy, APL has one of the highest 
cure rates of all types of AML. Seventy to eighty percent of 
newly diagnosed APL patients with the PML-RARA rear-
rangement are cured or under long-term remission, yet 
some of them have a poor prognosis [2-5]. Because cytoge-
netics is one of the most powerful prognostic factors for the 
outcome of AML, cytogenetic abnormalities can cause 
change in treatment response, relapse, and clinicopathologi-
cal characteristics [6]. Incidence of secondary cytogenetic 
abnormalities has been observed in ~40% of APL cases [1], 
but their prognostic significance is still unclear [5-7].
About 1% of the reported secondary cytogenetic abnor-
malities in APL patients are ider(17)(q10)t(15;17)(q22;q12), 
an infrequent type of additional recurrent chromosomal 
abnormality, according to a recent study [6]. However, 
ider(17)(q10)t(15;17) associated with the PML-RARA rear-
rangement in microgranular variant APL is even more rare. 
As far as we know, only 2 cases of the ider(17)(q10)t(15;17) 
abnormality in microgranular APL have been previously 
reported [8, 9]. Here, we describe an unusual microgranular 
APL case associated with ider(17)(q10)t(15;17), identified 
by both conventional cytogenetics and FISH analyses at the 
initial diagnosis. 
CASE REPORT
A 59-yr-old woman who had previously been diagnosed 
with cerebral infarction was brought to our hospital due to 
right side weakness in November 2007. The initial complete 
blood count showed pancytopenia, Hb level of 9.9 g/dL 
(reference range 12-16 g/dL), platelet count of 83,000/μL 
(reference range 150,000-350,000/μL), and white blood cell 
count of 1,000/μL (reference range 4,000-10,000/μL). Bone 
marrow aspiration showed a hypercellular marrow replaced Kim MJ, et al.  •  Microgranular APL with ider(17)(q10)
www.kjlm.org     87 DOI 10.3343/kjlm.2011.31.2.86
KJLM
by increased promyelocytes with a paucity or absence of 
granules, accounting for 36% of all nucleated cells (Fig. 1). 
The results of special staining of bone marrow specimens 
were as follows: Myeloperoxidase, positive; periodic acid 
Schiff, negative; Nonspecific esterase, negative. Flow cyto-
metric analysis was conducted and showed that the blasts 
were positive for CD13 (91.1%), CD33 (83.9%), CD117 
(59.2%), CD2 (43.9%), and CD45 (25.4%), and negative for 
HLA-DR (3.4%), CD3 (1.3%), CD7 (0.6%), CD10 (1.8%), 
CD14 (2.4%), CD19 (5.1%), CD34 (1.4%), CD41 (2.9%), 
CD56 (1.2%), and TdT (0.9%). Bone marrow chromosome 
analysis revealed a 46,XX,del(6)(?q21q25),der(15)t(15;17)
(q22;q12),ider(17)(q10)t(15;17)[10]/47,sl,+ider(17)(q10)
t(15;17)[3]/46,XX[16] (Fig. 2). FISH signals from PML-
RARA probes (Abbott Molecular/Vysis, Des Plaines, IL, 
USA) yielded the results of nuc ish(PML, RARA)×4(RARA 
con PML×3)[24/138], (PML, RARA)×6(RARA con PML× 
5)[14/138], (PML, RARA)×3(RARA con PML×2)[13/138], 
consistent with the abnormal fusion signal patterns seen in 
37% of the nuclei examined (Fig. 2). The patient was diag-
nosed with APL and treated with induction chemotherapy 
consisting of daunorubicin, cytosine arabinoside, and ATRA. 
After completing induction chemotherapy, follow up bone 
marrow examination in January 2008 showed no evidence 
of morphologically visible residual leukemia. The concurrent 
karyotype analysis result was 46,XX in all analyzed cells; and 
PML-RARA FISH showed “nuc ish (PML, RARA)×2 [248]” 
in which the abnormal signal pattern was not observed. 
There was no evidence of a PML-RARA fusion gene in the 
reverse transcriptase-PCR (RT-PCR) analysis. As indicated 
by follow-up bone marrow biopsies conducted until Septem-
ber 2008, the patient remained in complete remission. Dur-
Fig. 1. Bone marrow aspiration showing abnormal promyelocytes 
with sparse and/or fine granulation (dotted arrows), bilobed or 
“butterfly”-shaped nucleus (a horizontal arrow), cerebriform nucle-
us (an oblique arrow) and “salmon pink”-colored cytoplasm (a ver-
tical arrow) at diagnosis (Wright-Giemsa stain,×1,000).
B
C
Fig. 2. Chromosome and FISH studies at initial diagnosis. (A) Full 
karyogram of the bone marrow cells (major clone) at diagnosis: 
46,XX,del(6)(?q21q25),der(15)t(15;17)(q22;q12),ider(17)(q10)
t(15;17). The arrows indicate abnormal chromosomes in this 
karyogram. (B) Partial karyograms (chromosomes 15 and 17) of 
the bone marrow cells at diagnosis: Upper image: t(15;17)
(q22;q12) associated with ider(17)(q10)t(15;17). Lower image: 
t(15;17)(q22;q12) associated with double ider(17)(q10)t(15;17). (C) 
FISH study using a PML-RARA dual-color, dual-fusion transloca-
tion probe (Abbott Molecular/Vysis, USA) at diagnosis. The arrows indicate the PML-RARA or RARA-PML fusion signals. Left image: ider(17)
(q10)t(15;17) clone (3 fusion signals). Right image: double ider(17)(q10)t(15;17) clone (5 fusion signals).
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ing this period, the RT-PCR analysis did not show any signs 
of the PML-RARA fusion gene while other cytogenetic stud-
ies also indicated normal findings. 
DISCUSSION
APL is a distinct subtype of AML and constitutes about 
5-8% of all cases of AML diagnosis. According to the 2008 
WHO classification, APL can be diagnosed when there is a 
t(15;17) or a PML-RARA rearrangement, even if peripheral 
blood or bone marrow studies show less than 20% promy-
elocytes [1]. As recently reported by Manola et al. [10] and 
our study group, the ider(17)(q10)t(15;17), an isochromo-
somal abnormality that occurs on the long arm of ider(17)
t(15;17) after reciprocal translocation of t(15;17), is a rela-
tively rare type of an additional recurrent cytogenetic ab-
normality that has been reported in 62 APL patients world-
wide [8-13]. According to these studies, the influence of 
ider(17)(q10)t(15; 17) on the prognosis of adult APL pa-
tients is less significant than its effect on children. Indeed, 4 
previously reported APL cases in children were all related 
to poor prognosis [8, 13-15], inferring that a more close and 
careful interpretation is necessary for childhood APL cases 
[13]. What is interesting is that so far, reports of ider(17)
(q10)t(15;17) from microgranular variant (AML-M3v) type 
are extremely rare. Out of 62 total cases, information on 
APL morphology type were available in 42 cases, and most 
of these cases (40/42) were of the hypergranular APL type, 
except for 2 cases that clearly indicated AML-M3v (Table 1) 
[8, 9]. Therefore, further research is required to determine 
whether ider(17)(q10) and AML-M3v have a low associa-
tion, and more careful observation should be conducted to 
prevent underestimating AML-M3v patients among 
ider(17)(q10)t(15;17) cases. Furthermore, double ider(17)
Table 1. Comparison between previous 2 reports and present study with microgranular variant acute promyelocytic leukemia associated with ider(17)(q10)
t(15;17)(q22;q12)
Chou et al. [8] Kaleem et al. [9] Present case
Sex/age (yr) M/17 F/71 F/59
WBC (×10
9/L) 4.04 2.1 17.39
Karyotype ider(17)(q10)t(15;17)(q22;q12)* 47,XX,+8,t(15;17)(q22;q21),ider(17)(q10)
t(15;17)(q22;q12)
46,XX,del(6)(?q21q25),der(15)t(15;17)(q22;q21),ider(17)(q10)
t(15;17)(q22;q12)/47,sl,+ ider(17)(q10)t(15;17)(q22;q12)/46,XX
Immunophenotyping NA CD13+, CD33+, HLA-DR-, CD10-,  
CD14-, CD34-, CD41-, TdT-
CD13+, CD33+, CD117+, CD2+, CD45+
HLA-DR-, CD3-, CD7-, CD10-, CD14-, CD19-, CD34-, CD41-, CD56-, 
TdT-
PML-RARA rearrangement Positive (FISH, RT-PCR) NA Positive (FISH)
CR (month) 12 NA 35
Survival (month) 13 (dead) 36 (alive) 36 (alive)
ATRA therapy Y Y Y
* Full karyotype was not available and published karyotype was slightly modified to simplify nomenclature.
Abbreviations: M, male; F, female; WBC, white blood cell; NA, not available; FISH, fluorescent in situ hybridization; RT-PCR, reverse transcriptase-PCR; CR, complete remission; ATRA, 
all trans retinoic acid; Y, yes.
Table 2. Summary of acute promyelocytic leukemia patients with double ider(17)(q10)t(15;17)(q22;q12) from the literature and this study
No. case Sex Age
(yr) Morphology Karyotype* FISH RT-PCR 
for PML-RARA  ATRA therapy Relapse CR
(month)
Survival
(month) References
1 M 40 Hypergranular 
type
46,XY,t(15;17)(q22;q21)/47,XY,der(15)
t(15;17),+17,ider(17)(q10)t(15;17)x2
NA NA Y N Y 19 [16]
2 M 42 Hypergranular 
type
47,XY,del(1)(p?),der(15)t(15;17)
(q22;q21),+17,ider(17)(q10)t(15;17)x2
NA NA N N Y 120 [17]
3 F 59 Microgranular 
variant type
46,XX,del(6)(?q21q25),der(15)t(15;17)
(q22;q21),ider(17)(q10)t(15;17)
(q22;q12)/47,sl,+ ider(17)(q10)t(15;17)
(q22;q12)/46,XX
Y NA Y N 35 36 Present 
study
* Some published karyotypes were slightly modified to simplify nomenclature.
Abbreviations: FISH, fluorescent in situ hybridization; RT-PCR, reverse transcriptase-PCR; ATRA, all trans-retinoic acid; CR, complete remission; M, male; F, female; NA, not available; 
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(q10)t(15;17) is so rare in the International Public Data-
bases that only 2 cases of APL patients indicating double 
ider(17)(q10)t(15;17) chromosomal abnormalities have 
been reported (Table 2) [16, 17]. In double ider(17)(q10)
t(15;17), a gene dosage effect is observed owing to chromo-
somal abnormalities such as the PML-RARA fusion gene 
on chromosome 17 or the quadruplication of der(17q). In 
addition, since the deletion of the tumor suppressor gene 
TP53 occurs by the loss of 17p, further research is necessary 
to resolve the adverse prognosis of the APL group related to 
such copy number variations. Owing to the limited amount 
of clinical data in the literature, the relatedness between 
double ider(17)(q10)t(15;17) and an adverse prognosis is 
still unclear [16, 17]. In the case of our patient, it was hard 
to determine a strong association between the additional 
genetic aberration and prognosis because of the small clonal 
size of the “double ider(17)(q10)t(15;17)” abnormality.
Nevertheless, at least from a diagnostic perspective and as 
indicated in the authors’ recent studies [13, 18], minimal re-
sidual disease detection using such multiple abnormal fu-
sion signals through the PML-RARA FISH analysis in APL 
patients associated with ider(17)(q10)t(15;17) or double 
ider(17)(q10)t(15;17) would be considered to be a useful 
follow-up marker in clinical laboratories or hospitals. Addi-
tional study would contribute toward a better understand-
ing of the influence of ider(17)(q10)t(15;17) on the progno-
sis, survival, and treatment response of such APL cases in 
adults or children. To the best of our knowledge, however, 
this is the third case report of microgranular variant APL 
associated with ider(17)(q10)t(15;17).
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